Coherus Oncology, Inc. (CHRS): Operating Cash Flow
-$138.51M
Year ended 2025-12-31
-$186.03M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$138.51M | n/m | 2026-03-09, From 2025-01-01 |
| 2024-12-31 | -$20.44M | n/m | 2026-03-09, From 2024-01-01 |
| 2023-12-31 | -$174.88M | n/m | 2025-03-17, From 2023-01-01 |
| 2022-12-31 | -$241.12M | n/m | 2025-03-17, From 2022-01-01 |
| 2021-12-31 | -$37.43M | n/m | 2024-03-15, From 2021-01-01 |
| 2020-12-31 | $154.15M | +443.6% | 2023-03-06, From 2020-01-01 |
| 2019-12-31 | $28.36M | n/m | 2022-02-23, From 2019-01-01 |
| 2018-12-31 | -$159.27M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | -$200.29M | n/m | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | -$252.54M | n/m | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | -$107.99M | n/m | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | -$23.93M | n/m | 2017-03-14, From 2014-01-01 |
| 2013-12-31 | $15.42M | n/m | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | -$18.25M | n/a | 2015-03-23, From 2012-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | 2025-12-31 | -$138.51M | n/m |
| Tectonic Therapeutic, Inc. (TECX) | 2025-12-31 | -$60.08M | n/m |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | -$132.47M | n/m |
| Lexeo Therapeutics, Inc. (LXEO) | 2025-12-31 | -$98.56M | n/m |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | -$73.21M | n/m |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | -$46.36M | n/m |
| Invivyd, Inc. (IVVD) | 2025-12-31 | -$58.13M | n/m |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | -$121.18M | n/m |
| Solid Biosciences Inc. (SLDB) | 2025-12-31 | -$156.29M | n/m |
Compare CHRS, TECX, VYGR, LXEO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗